Vilanterol Trifenatate + Fluticasone Furoate

This preparation contains both fluticasone furoate and vilanterol, and the mechanisms of action of each are described below. They belong to 2 different classes of medicine, a synthetic corticosteroid and a LABA, and they act differently on the clinical and physiological side.

The effects of beta 2-adrenoceptor agonist drugs, vilanterol included, are at least partly due to stimulation of intracellular adenyl cyclase. This is the enzyme that converts adenosine triphosphate (ATP) into cyclic-3, 5-adenosine monophosphate (cyclic AMP). When cyclic AMP levels rise, bronchial smooth muscle relaxes and cells, especially mast cells, release fewer mediators of immediate hypersensitivity.

The exact way fluticasone furoate affects COPD and asthma symptoms is not known. Inflammation is an important part of how COPD and asthma develop. Corticosteroids have been shown to act on many cell types (for example mast cells, eosinophils, neutrophils, macrophages and lymphocytes) and on many mediators (for example histamine, eicosanoids, leukotrienes and cytokines) involved in inflammation.